Company intelligence / Profile preview

Amkor Pharma

Washington, United Statesamkor.com ↗

Ownership: Private
Development stage: Commercial

Overview

Amkor Pharma's lead asset, salfaprodil—a GluN2B antagonist—has reached Phase 3 clinical trials for acute ischemic stroke. The drug has also been investigated for myocardial infarction and brain injuries. No detailed clinical results are publicly available as of June 2025.

Therapeutic areas: CardiovascularNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Amkor Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amkor Pharma.

Explore the full profile